Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.

Article  PubMed  Google Scholar 

Wang G, Huang Y, Zhou L, Yang H, Lin H, Zhou S, Tan Z, Qian J. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer. Crit Rev Oncol Hematol. 2023;198:104197.

Article  PubMed  Google Scholar 

Zhao K, Na Y, Xu HM. Advances in translational therapy for locally advanced gastric cancer. World J Clin Cases. 2023;11(11):2405–11.

Article  PubMed  PubMed Central  Google Scholar 

Liu C, Li S, Tang Y. Mechanism of cisplatin resistance in gastric cancer and associated microRNAs. Cancer Chemother Pharmacol. 2023;92(5):329–40.

Article  CAS  PubMed  Google Scholar 

Hu H, Li B, Wang J, Tan Y, Xu M, Xu W, Lu H. New advances into cisplatin resistance in head and neck squamous carcinoma: mechanisms and therapeutic aspects. Biomed Pharmacother. 2023;163: 114778.

Article  CAS  PubMed  Google Scholar 

Stulpinas A, Tenkutyte M, Imbrasaite A, Kalvelyte AV. The role and efficacy of JNK inhibition in inducing lung cancer cell death depend on the concentration of cisplatin. ACS Omega. 2024;9(26):28311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demuytere J, Carlier C, Van Helden T, Belza J, Vanhaecke F, Xie F, Vermeulen A, Weerts J, Thomale J, Denys H, et al. Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases: results from a randomized trial in ovarian cancer. Br J Surg. 2024. https://doi.org/10.1093/bjs/znae078.

Article  PubMed  Google Scholar 

Dasari S, Njiki S, Mbemi A, Yedjou CG, Tchounwou PB. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int J Mol Sci. 2022;23(3):1532.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riddell IA. Cisplatin and oxaliplatin: our current understanding of their actions. Met Ions Life Sci. 2018. https://doi.org/10.1515/9783110470734-001.

Article  PubMed  Google Scholar 

Golbashirzadeh M, Heidari HR, Talebi M, Yari Khosroushahi A. Ferroptosis as a potential cell death mechanism against cisplatin-resistant lung cancer cell line. Adv Pharm Bull. 2023;13(1):176–87.

CAS  PubMed  Google Scholar 

Posadino AM, Giordo R, Pintus G, Mohammed SA, Orhan IE, Fokou PVT, Sharopov F, Adetunji CO, Gulsunoglu-Konuskan Z, Ydyrys A, et al. Medicinal and mechanistic overview of artemisinin in the treatment of human diseases. Biomed Pharmacother. 2023;163: 114866.

Article  CAS  PubMed  Google Scholar 

Olatunde OZ, Yong J, Lu C. An overview of dihydroartemisinin as a promising lead compound for development of anticancer agents. Mini Rev Med Chem. 2023;23(3):265–89.

Article  CAS  PubMed  Google Scholar 

Yang J, Xia T, Zhou S, Liu S, Pan T, Li Y, Luo Z. Anticancer effect of Dihydroartemisinin via dual control of ROS-induced apoptosis and protective autophagy in prostate cancer 22Rv1 cells. Curr Pharm Biotechnol. 2023. https://doi.org/10.2174/1389201024666230821155243.

Article  PubMed  Google Scholar 

Wang Y, Yang Z, Zhu W, Chen Y, He X, Li J, Han Z, Yang Y, Liu W, Zhang K. Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling. Drug Dev Res. 2023;84(5):988–98.

Article  CAS  PubMed  Google Scholar 

Peng Q, Hao L, Guo Y, Zhang Z, Ji J, Xue Y, Liu Y, Li C, Lu J, Shi X. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma. J Nat Med. 2023;77(1):28–40.

Article  CAS  PubMed  Google Scholar 

Han N, Yang ZY, Xie ZX, Xu HZ, Yu TT, Li QR, Li LG, Peng XC, Yang XX, Hu J, et al. Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy. Phytomedicine. 2023;112: 154682.

Article  CAS  PubMed  Google Scholar 

Grignano E, Cantero-Aguilar L, Tuerdi Z, Chabane T, Vazquez R, Johnson N, Zerbit J, Decroocq J, Birsen R, Fontenay M, et al. Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein. Cell Death Discov. 2023;9(1):97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Ding Q, Zhou H, Huang C, Liu G, Zhao X, Cheng Z, You X. Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway. Phytomedicine. 2024;134: 155962.

Article  CAS  PubMed  Google Scholar 

Kachadourian R, Leitner HM, Day BJ. Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. Int J Oncol. 2007;31(1):161–8.

CAS  PubMed  Google Scholar 

Li Q, Zhang Y, Yang Y, Huang S, Zou X, Wei C, Liang T, Zhong X. Panax notoginseng saponins reduces the cisplatin-induced acute renal injury by increasing HIF-1alpha/BNIP3 to inhibit mitochondrial apoptosis pathway. Biomed Pharmacother. 2021;142: 111965.

Article  CAS  PubMed  Google Scholar 

Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Matsui K, Takifuji N, Morino H, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res. 1993;84(2):203–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial. JAMA Oncol. 2019;5(6):833–40.

Article  PubMed  PubMed Central  Google Scholar 

Tang T, Xia Q, Xi M. Dihydroartemisinin and its anticancer activity against endometrial carcinoma and cervical cancer: involvement of apoptosis, autophagy and transferrin receptor. Singapore Med J. 2021;62(2):96–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Lu X, Li Z, Sun Y, He Z, Li X. Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment. Onco Targets Ther. 2020;13:3375–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Ma Q, Xu L, Gao C, Yao L, Wen J, Yang M, Cheng J, Zhou X, Zou J, et al. Human telomerase reverse transcriptase as a therapeutic target of dihydroartemisinin for esophageal squamous cancer. Front Pharmacol. 2021;12: 769787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo J, Odaka Y, Huang Z, Cheng B, Liu W, Li L, Shang C, Zhang C, Wu Y, Luo Y, et al. Dihydroartemisinin inhibits mTORC1 signaling by activating the AMPK pathway in rhabdomyosarcoma tumor cells. Cells. 2021;10(6):1363.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang JL, Wang Z, Hu W, Chen SS, Lou XE, Zhou HJ. DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma. Microvasc Res. 2013;87:14–24.

Article  CAS  PubMed